PRESCIENT THERAPEUTICS LIMITED The Company Announcements Platform ASX Limited
By E-lodgement
Share Purchase Plan Completion
Prescient confirms that it has issued 17,174,368 fully paid ordinary shares raising $927,421.17 with the issue price being set at $0.054 (5.4 cents) per share, being a 20% discount to the 5 day volume weighted average price (VWAP) before 23 November 2015.
A total amount of $1,201,500 was subscribed for under the Offer and all applicants have been scaled back on an equal basis as the Company was only permitted to accept a maximum of 30% of its issued capital prior to the Offer. All oversubscriptions will be refunded to shareholders in the coming weeks.
An Appendix 3B is attached providing a summary of the issued capital of the Company following the completion of the Offer.
The Board thanks all shareholders for their continued support and level of interest shown through this SPP.
Executive Director Monsoon Communications
+61 406 671 515 +61 (0) 3 9620 3333
PTX is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.
Lead drug candidate PTX-200 inhibits an important tumor survival pathway known as AKT, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukaemia. This highly promising compound is now the focus of two current clinical trials. The first is a Phase 1b/2 study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York. A Phase 1b/2 trial of the compound in
Prescient Therapeutics Limited
Level 4, 100 Albert Road, South Melbourne, VIC 3205
Phone: +61 3 9692 7222 Fax: +61 3 9077 9233
ABN: 56 006 569 106 ACN: 006 569 106
www.prescienttherapeutics.com
combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at Florida's H. Lee Moffitt Cancer Center. These trials are funded in part by grants from the U.S. National Cancer Institute. In addition, PTX is planning a Phase 1b/2 trial evaluating PTX-200 as a new therapy for acute myeloid leukemia.
PTX's second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase (GGT). It also blocks the Ral and Rho circuits in cancer cells which act as key oncogenic survival pathways, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase 1 trial in advanced solid tumors.
PTX has licensed access to its Co-X-Gene™ platform technology to French biotechnology company Transgene for use in two immunotherapeutic products.
Prescient Therapeutics Limited
Level 4, 100 Albert Road, South Melbourne, VIC 3205
Phone: +61 3 9692 7222 Fax: +61 3 9077 9233
ABN: 56 006 569 106 ACN: 006 569 106
www.prescienttherapeutics.com
Appendix 3B New issue announcement
Rule 2.7, 3.10.3, 3.10.4, 3.10.5
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.
Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12
Name of entity |
Prescient Therapeutics Limited |
ABN |
56 006 569 106 |
We (the entity) give ASX the following information.
Part 1 - All issuesYou must complete the relevant sections (attach sheets if there is not enough space).
1 | +Class of +securities issued or to be issued |
|
2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued | 1. 17,174,368 2. 700,000 3. 200,000 |
3 | Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion) |
|
+ See chapter 19 for defined terms.
01/08/2012 Appendix 3B Page 1
Appendix 3B
New issue announcement
4 | Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities? If the additional securities do not rank equally, please state:
| 1. Yes - fully paid ordinary shares 2 & 3. The options are not quoted Shares issued upon the exercise of options will rank equally with fully paid shares on issue. |
5 | Issue price or consideration |
|
6 | Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) |
|
6a | Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i | Yes |
6b | The date the security holder resolution under rule 7.1A was passed | 4 November 2015 |
6c | Number of +securities issued without security holder approval under rule 7.1 | 200,000 unlisted options |
6d | Number of +securities issued with security holder approval under rule 7.1A | Nil |
6e | Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting) | 700,000 unlisted options - approval date 4 November 2015 |
6f | Number of securities issued under an exception in rule 7.2 | 17,174,368 fully paid ordinary shares |
+ See chapter 19 for defined terms.
Appendix 3B Page 2 01/08/2012
|
distributed by
|
